Equities analysts predict that Icon Plc (NASDAQ:ICLR) will report $676.22 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Icon’s earnings, with estimates ranging from $669.50 million to $693.25 million. Icon reported sales of $455.14 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 48.6%. The company is expected to issue its next earnings report on Thursday, February 21st.
According to Zacks, analysts expect that Icon will report full-year sales of $2.59 billion for the current year, with estimates ranging from $2.59 billion to $2.61 billion. For the next financial year, analysts forecast that the company will report sales of $2.79 billion, with estimates ranging from $2.77 billion to $2.83 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Icon.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, meeting the consensus estimate of $1.54. The business had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million. Icon had a net margin of 12.88% and a return on equity of 26.75%.
Shares of ICLR stock traded up $0.04 during trading hours on Tuesday, hitting $134.85. The company’s stock had a trading volume of 2,077 shares, compared to its average volume of 282,057. The firm has a market capitalization of $7.49 billion, a PE ratio of 25.30, a P/E/G ratio of 1.98 and a beta of 0.31. Icon has a twelve month low of $101.22 and a twelve month high of $155.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.10 and a quick ratio of 2.10.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. WCM Investment Management CA boosted its position in Icon by 3.9% during the second quarter. WCM Investment Management CA now owns 4,633,580 shares of the medical research company’s stock worth $614,088,000 after acquiring an additional 172,080 shares during the last quarter. Renaissance Technologies LLC raised its stake in Icon by 0.6% during the second quarter. Renaissance Technologies LLC now owns 1,933,360 shares of the medical research company’s stock worth $256,228,000 after purchasing an additional 10,600 shares during the period. Boston Partners raised its stake in Icon by 2.4% during the second quarter. Boston Partners now owns 1,665,259 shares of the medical research company’s stock worth $220,696,000 after purchasing an additional 38,819 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Icon by 12.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock worth $164,561,000 after purchasing an additional 121,970 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Icon by 20.6% during the first quarter. Principal Financial Group Inc. now owns 946,806 shares of the medical research company’s stock worth $111,856,000 after purchasing an additional 161,558 shares during the period. Hedge funds and other institutional investors own 87.38% of the company’s stock.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.